SCHEMBL4840336

SCHEMBL4840336

N#Cc1nc(N2CCOCC2)c2ncn(-c3ccccc3Cl)c2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.43
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPK1 P28482 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 1/20 0.40
PRKDC P78527 1/20 0.39
ADORA2A P29274 1/20 0.39
PDE10A Q9Y233 2/20 0.39
GAA P10253 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 2/20 0.37
MAPT P10636 2/20 0.37
PIK3CA P42336 2/20 0.37
PIK3CB P42338 1/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
RAD51 Q06609 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6247986 0.89 CSNK1D (0.41) CTSKPRKDCRAD51
SCHEMBL4847924 0.83 PRKDC (0.45) CTSKKDM4EALDH1A1MAPK1HSD17B10
SCHEMBL4848260 0.81 XDH (0.44) CTSKKDM4EALDH1A1MAPK1HSD17B10
SCHEMBL4846208 0.78 CTSK (0.45) CTSKKDM4EALDH1A1MAPK1HSD17B10
SCHEMBL4846228 0.77 POLB (0.44) KDM4EALDH1A1HPGDPDE10AGAA
SCHEMBL4846408 0.76 CTSK (0.48) CTSKKDM4EALDH1A1PRKDCPDE10A
SCHEMBL4848945 0.76 CSNK1E (0.47) CTSKPRKDC
SCHEMBL4844175 0.75 CNR2 (0.40) KDM4EALDH1A1HSD17B10PDE10AGAA
SCHEMBL4848132 0.74 PRKDC (0.41) CTSKKDM4EPRKDCPIK3CA
SCHEMBL4848305 0.72 XDH (0.42) CTSKKDM4EALDH1A1MAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439240-B2 Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity ASTRAZENECA AB (SE) 2008-10-21 US claimed
EP-1532148-B1 NOVEL PURINE- OR PYRROLOL(2,3-D)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY ASTRAZENECA AB (SE) 2007-01-17 EP claimed
US-20050203107-A1 Reversible inhibitors of cysteine proteases S, K, F, L and B; inhibiting Cathepsin S; analgesics; 1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide for example ASTRAZENECA AB (SE) 2005-09-15 US claimed
US-7439240-B2 Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity ASTRAZENECA AB (SE) 2008-10-21 US disclosed
US-20080125426-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-05-29 US disclosed
US-20080119469-A1 1-(4-methylphenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidine-6-carbonitrile; reversible inhibitors of cysteine proteases S, K, F, L, B; diseases associated with Cathepsin S; antiinflammatory agent, autoimmune diseases; asthma, rheumatoid arthritis, multiple sclerosis, Crohn's, Alzheimer's diseases ASTRAZENECA AB (SE) 2008-05-22 US disclosed
EP-1532148-B1 NOVEL PURINE- OR PYRROLOL(2,3-D)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY ASTRAZENECA AB (SE) 2007-01-17 EP disclosed
US-20050203107-A1 Reversible inhibitors of cysteine proteases S, K, F, L and B; inhibiting Cathepsin S; analgesics; 1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide for example ASTRAZENECA AB (SE) 2005-09-15 US disclosed
EP-1532148-A1 NOVEL PURINE- OR PYRROLOL(2,3-D)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AstraZeneca AB (SE) 2005-05-25 EP disclosed
WO-2004000843-A1 NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY ASTRAZENECA AB (SE) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119469-A1 1-(4-methylphenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidine-6-carbonitrile; reversible inhibitors of cysteine proteases S, K, F, L, B; diseases associated with Cathepsin S; antiinflammatory agent, autoimmune diseases; asthma, rheumatoid arthritis, multiple sclerosis, Crohn's, Alzheimer's diseases CTSS, CTSB, CTSL CTSK 4/4885KDM4E 748/4885ALDH1A1 2991/4885
US-20080125426-A1 Novel Compounds CTSS, CTSB, CTSF CTSK 8/4885KDM4E 2837/4885ALDH1A1 3421/4885
US-20050203107-A1 Reversible inhibitors of cysteine proteases S, K, F, L and B; inhibiting Cathepsin S; analgesics; 1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide for example CTSB, CTSL, CTSS CTSK 4/4885KDM4E 1399/4885ALDH1A1 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.